If you have wondered whether you still need a COVID-19 shot this year, you are not alone. Federal health officials are reportedly considering a major shift that could limit recommendations to the oldest Americans, even as questions swirl about safety claims tied to children. According to the Washington Post, citing four unnamed sources familiar with internal talks, officials under Health and Human Services Secretary Robert F. Kennedy Jr. are preparing to allege mRNA COVID-19 vaccines caused 25 pediatric deaths and are weighing new restrictions on access.
The reported plan could tighten guidance so that routine vaccination is recommended only for people 75 and older, with others told to consult their physicians. Such a move would mark a sharp departure from prior nationwide practice and could complicate insurance coverage, supply planning, and public understanding. The discussions are said to be timed to an upcoming meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, now populated by new members selected by Kennedy.
What the reports say
The Post reports that officials are leaning on entries in the Vaccine Adverse Event Reporting System, or VAERS, to support assertions of vaccine-caused child deaths. VAERS is an open, early warning system where anyone can submit a report, and those submissions are unverified at entry. Safety experts use VAERS as a starting point and then perform follow up to assess plausibility and causation.
The alleged plans have raised alarms in the medical community because they would rely on raw reports rather than completed investigations. They also arrive amid a broader reshaping of federal health advisory bodies, which critics say risks politicizing routine immunization guidance.
What safety data show
Across billions of mRNA doses administered worldwide, CDC scientists, international counterparts, and academic researchers have consistently found a strong safety profile. Known risks include rare heart inflammation, myocarditis and pericarditis, with the highest incidence in males ages 12 to 24 at roughly 27 cases per million doses. Most cases have been mild and resolved with rest and standard treatment.
CDC data do not show a linkage between mRNA vaccination and deaths or heart transplants, and across all ages, overall mortality is lower among vaccinated individuals than the general population. Pharmacovigilance relies on multiple systems, including active surveillance and medical record review, to move from a reported event to a confirmed safety signal. Experts caution that using unverified VAERS entries to justify sweeping policy shifts breaks with established norms.
Pediatric COVID-19 deaths in context
Since July 2023, 25 children have died from COVID-19 infection, not vaccination, according to data cited in internal discussions. Of those, 16 were eligible for vaccination at the time. Fourteen had no record of receiving a dose, and none were current on vaccination.
While severe COVID-19 remains less common in children than in older adults, pediatric deaths and hospitalizations continue, particularly among infants and children with underlying conditions. Pediatricians stress that prevention through vaccination reduces risk for both children and the people around them.
Kennedy’s record and agency shake-ups
During the pandemic, Kennedy petitioned the FDA to withdraw authorization for COVID-19 vaccines and to block future approvals. He has repeatedly advanced unsupported claims that mRNA vaccines are responsible for child deaths, frequently citing VAERS as evidence. Since becoming HHS Secretary, Kennedy has installed allies who share skepticism of mRNA technology and pandemic public health measures.
He canceled nearly half a billion dollars in grants intended to advance mRNA platforms for future pandemic preparedness. In June, the CDC dismissed all 17 sitting members of its Advisory Committee on Immunization Practices and quickly replaced them with members aligned with Kennedy’s views, with additional appointments still being considered.
Where access stands now
FDA policy under Kennedy has already scaled back product approvals. Availability that once covered people 6 months and older now primarily applies to adults 65 and up, with younger people eligible only if they meet specific medical risk criteria. The lack of timely ACIP recommendations this year has compounded access challenges for providers, payers, and the public.
Pharmacies and clinics often rely on ACIP guidance to secure reimbursement and order inventory. Absent clear recommendations, appointment scheduling and insurance coverage become uncertain, which can suppress uptake even among those who remain eligible.
What ACIP could do next
ACIP is scheduled to meet September 18 to 19 to discuss COVID-19 vaccines along with Hepatitis B, MMRV, and RSV. Options reportedly include recommending COVID-19 vaccination only for those 75 and older and advising others to consult their physicians. Another option would be to withhold recommendations entirely for people under 75 unless they have preexisting risk conditions.
Either path would further constrain access and would depart from prior evidence-based practices that weighed population level benefits. It would also set the tone for how commercial payers and state programs handle coverage through the respiratory virus season.
Backlash from clinicians and lawmakers
Major medical and public health organizations have issued independent guidance reaffirming COVID-19 vaccination for healthy children, especially those under age 2, for pregnant people, and for healthy adults. Criticism of Kennedy’s actions has been bipartisan. Sen. Bill Cassidy, a physician and vaccine supporter who voted to confirm Kennedy, has urged postponement of the ACIP meeting, citing concerns about the agenda, membership integrity, and scientific rigor.
More than 1,000 current and former HHS staff, multiple medical societies, and several lawmakers have called for Kennedy to step down. Their concern centers on preserving scientific standards and public trust during a period of fast moving respiratory threats.
Congress pushes back on mRNA funding cuts
Responding to HHS grant cancellations, the House Appropriations Committee advanced a 2026 bill that earmarks pandemic preparedness funds at BARDA for advanced research and development, including mRNA vaccines. The bill specifies $1.1 billion available through fiscal year 2027, signaling continued legislative support for the technology.
If enacted, that funding would counterbalance agency level skepticism and maintain a pipeline for next generation vaccine platforms. It would also give manufacturers and research partners more certainty as they plan clinical trials and scale production.
Why this matters now
Further restricting recommendations could deepen public distrust and create regional patchworks in access. Insurers, pharmacies, and clinics depend on clear federal guidance to cover and deliver shots efficiently. Sudden pivots, especially those that lean on unverified reports, risk undermining well established safety surveillance norms.
With the ACIP meeting approaching, the clash between federal health leadership and the broader medical community shows no signs of easing. What happens next will shape vaccination access and confidence through the fall and winter, and it will set a precedent for how the United States manages vaccine policy in the next public health emergency.